

Index

A

Acid-sphingomyelinase (ASMase), 109
Actin cytoskeleton, 122, 124
Action to Control Cardiovascular Risk in Diabetes (ACCORD), 44
Activating transcription factor 6 (ATF6), 49
Acute kidney injury (AKI), 4, 45, 54
Adrenocorticotropic hormone (ACTH), 56, 108, 133
Advanced glycation end products (AGEs), 47, 55
African-American Study of Kidney Disease and Hypertension (AASK) trial, 3
Albumin endocytosis, 15
Albumin-to-creatinine ratio (ACR), 6
Albuminuria, 42, 89, 93
 α -smooth muscle actin (α -SMA), 33, 46
Amiloride, 96
Angiotensin (Angpt), 16
Angiotensin-converting enzyme (ACE), 43, 54
Angiotensin converting enzyme inhibitor (ACEi), 5, 6, 131
Angiotensin receptor blockers (ARBs), 5, 6
Angiotensin II receptor blocker (ARB), 54, 131
Angiotensin II Type I (AT1) Receptor, 71
Angptl-4, 91, 93, 94
Antigen presenting cells (APCs), 75
Apolipoprotein L1 (APOL1), 17, 120, 122
Apoptosis, 33–34
Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN), 103
ASCEND trial, 56
Atherosclerosis Risk in Communities study, 4
Azathioprine, 108

B

Bardoxolone, 31, 55
BEACON trial, 55
Blood urea nitrogen (BUN), 98
Bovine serum albumin, 74
Bowman's capsule, 12, 125
Brain abundant signal protein 1 (BASP1), 33
Buffalo Mna rats, 93

C

C1q deposits, 94, 95
C3 glomerulopathy (C3G), 75
Calcineurin inhibitors (CNIs), 122, 132
Calcium, 98
Captopril, 5
Cardiotrophin-like cytokine 1 (CLC-1), 119
CD80, 88–90, 92, 93, 99, 102, 134
Chronic Renal Insufficiency Cohort (CRIC), 4
C-mip, 88
Cortical collecting tubule (CCT), 96
Corticosteroids, 102
C-X-C chemokine ligand 12 (CXCL12), 16
C-X-C chemokine receptor 4 (CXCR4), 16
Cyclophosphamide, 134
Cyclosporine, 102
Cytomegalovirus (CMV), 123
Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), 88, 92, 93

D

Damage-associated molecular patterns (DAMPs), 34, 47
DCCT-EDIC study, 52

- Diabetic kidney disease (DKD). *See* Diabetic nephropathy
- Diabetic nephropathy
- AKI, 45
 - albuminuria, 42, 44
 - biopsy-proven, 43
 - DKD, 42
 - hyperfiltration, 44
 - pathophysiology
 - AGEs, 47
 - ER, 49
 - endothelial cells, 51–52
 - hemodynamic changes, 45–46
 - inflammatory cytokines, 49
 - kidney fibrosis, 46
 - miRNAs, 50
 - MMPs, 47
 - oxidative stress, 48
 - podocyte injury, 50–51
 - TIMPs, 47
 - renal biopsy, 44
 - T2DM, 43, 44
 - T2DN, 44
 - treatment
 - ACEI and ARB therapy, 54
 - ACTH, 56
 - AGE, 55
 - AKI, 54
 - ET-1, 56
 - glycemic control, 52
 - hypertension, 53
 - lipid-lowering agents, 53
 - pentoxifylline, 56
 - protein restriction, 53
 - RAAS, 55
 - uric acid, 56
 - vitamin D deficiency, 56
 - weight loss, 53
 - UAE, 42
- Domino-like effect, 124
- E**
- Edema, 95
- Electrolytes, 97
- Electron microscopy, 95
- Endoplasmic reticulum (ER), 49
- Endothelial cells, 90, 91
- Endothelial surface layer (ESL), 51
- Endothelin receptor antagonists (ERAs/ET-1), 6, 7, 56
- End-stage renal disease (ESRD), 3, 128–130, 132, 133
- Epithelial sodium channels (ENaC), 96
- Epstein-Barr virus (EBV), 123
- Estimated glomerular filtration rate (eGFR), 132
- Extended therapy, 103
- Extracellular matrix (ECM), 45
- F**
- Fc receptor (FcRn), 28–30
- Focal segmental glomerulosclerosis (FSGS)
- clinical features
 - epidemiology, 128
 - presentation, 128, 129
 - prognosis, 129, 130
 - definition, 118
 - histological type, 125, 126, 128
 - pathology, 124, 125
 - primary
 - CLC-1, 119
 - idiopathic, 118
 - suPAR, 119
 - secondary
 - adaptive response, 123, 124
 - drugs, 122, 123
 - genetics, 120, 122
 - infections, 123
 - treatment, 130
 - alternatives to steroids, 132
 - conservative management, 131
 - corticosteroids, 131, 132
 - current clinical trials, 134
 - recurrence after transplantation, 134
 - relapse, 132
 - steroid-dependent, 132, 133
 - steroid-resistant, 133
- Foot process effacement, 124
- G**
- Glomerular antibody deposition, 72–75
- C3G, 75
 - clinical manifestations, 72
 - complement system, 73
 - Fc receptors, 73–74
 - MN, 74–75
 - subendothelial, 72
- Glomerular basement membrane (GBM), 13, 88, 89, 91, 93, 95
- Glomerular capillary wall, 68–70
- endothelium, 90
 - glomerular basement membrane, 91
 - podocytes, 91
- Glomerular endothelial cells (GECs), 12–13

- Glomerular filtration barrier (GFB)
 GBM, 13
 GECs, 12–13
 podocyte
 albumin endocytosis, 15
 autocrine and paracrine factors, 15–16
 deleterious effects, albumin, 17
 genetic mutations, 16–17
 glomerular tuft, 13
 schematic diagram, 13
 structure, 14
- Glomerular hydrostatic pressure, 123
 Glomerular sieving coefficient (GSC), 15
 Glomeruli, 88, 90, 94
 Glycosaminoglycans (GAGs), 12, 89
- H**
- Hemodynamic stress, 124
 Heroin-associated nephropathy (HAN), 122
 HIV-associated nephropathy (HIVAN), 123
 Hodgkin's disease, 88
 Hyperfiltration, 45, 46
 Hyperlipidemia, 97, 101, 106
 Hypoalbuminemia, 95–97, 100, 106
 Hypocalcaemia, 97
 Hypogammaglobulinemia, 98
 Hyponatremia, 97
 Hypovolemia, 95, 100
- I**
- Idiopathic nephrotic syndrome (INS), 88, 89
 IgA nephropathy, 125
 Immune-complex (IC)
 C3G, 75
 clinical manifestations, 72
 complement system, 73
 Fc receptors, 73–74
 MN, 74–75
 subendothelial, 72
- Immune-mediated mechanisms of injury, 72, 78
 autoimmune diseases and cancer, 78
 CD80 ligands, 77
 glomerular antibody deposition
 (*see* Glomerular antibody deposition)
 glomerular capillary wall, 68–70
 nephrotic syndrome (*see* Nephrotic syndrome)
 TLRs, 75–77
- Immunofluorescence, 86, 93, 94
 Immunoglobulin (IgG) levels, 98
 Immunosuppression, 131
 alternatives to steroids, 132
 corticosteroids, 131, 132
 current clinical trials, 134
 recurrence after transplantation, 134
 relapse, 132
 steroid-dependent FSGS, 132, 133
 steroid-resistant FSGS, 133
- Induction therapy, 102–104
 Interleukin-4 (IL-4), 88
 International Study of Kidney Disease of Children (ISKDC), 96, 102, 103, 105–108
- J**
- Japan Cooperative Study Group of Kidney Disease in Children, 103, 104
 Joint National Committee (JNC)
 8 guideline, 53
- K**
- Kidney Disease: Improving Global Outcomes (KDIGO), 53, 103, 104, 131
- L**
- Levamisole, 108
 Liddle syndrome, 96
 Light microscopy, 94
 Lipopolysaccharide (LPS) injection, 92
- M**
- Maladaptive scarring, 123
 Mannose binding lectin (MBL) pathway, 73
 Mechanistic target of rapamycin (mTOR)
 inhibitor, 122
 Megalin-Cubilin Complex, 27–28
 Membranoproliferative glomerulonephritis (MPGN), 70
 Membranous nephropathy (MN), 73–75
 Metalloproteinases (MMPs), 47
 Micropuncture technique, 96
 MicroRNAs (miRNAs), 50
 Minimal change disease (MCD)
 after steroid treatment, 105
 BUN, 98
 calcium and vitamin D, 97, 98
 clinical manifestation, 95, 96
 complement and IgG levels, 98
 definition, 86
 electrolytes, 97
 epidemiology, 87
 etiology, 87–88
 frequent relapsing and steroid dependency, 106–107

- Minimal change disease (MCD) (*cont.*)
 hematology, 97
 hyperlipidemia, 97
 hypoalbuminemia, 96, 97
 medications
 ACTH, 108
 azathioprine, 108
 levamisole, 108
 mizoribine, 108
 rituximab, 109–110
 natural course, 98–100
 pathogenesis
 clinical and pathological observations, 88
 cytokines, 88, 89
 T-cell disorder, 88
 pathological features
 electron microscopy, 95
 immunofluorescence microscopy, 94
 light microscopy, 94
 proteinuria control, 101
 induction therapy, 102–104
 tapering therapy, 104
 proteinuria mechanism, 90
 capillary wall anionic charges, 89
 glomerular capillary wall (*see*
 Glomerular capillary wall)
 podocyte disease (*see* Podocyte
 disease)
 serum creatinine, 98
 steroid therapy in relapse, 105, 106
 symptomatic therapy
 diet, 100
 edema, 100, 101
 hyperlipidemia, 101
 immunizations, 101
 infections, 101
 physical activity, 100
 urinalysis, 96
 Mizoribine, 108
 Modification of Diet in Renal Disease
 (MDRD), 3
 Munich-Wistar Fromter (MWF) rats, 26
 Mycophenolate mofetil (MMF), 131
 Myofibroblast, CKD, 46
 Myosin heavy chain 9 (MYH9), 120
- N**
 N-acetylmannosamine (ManNAc), 93
 Na(+)/H(+) exchanger isoform 3 (NHE3), 31
 National Health and Nutrition Examination
 Survey (NHANES), 3
 National Kidney Disease Education Program
 (NKDEP), 44
- Nephrin, 88, 90, 91, 93, 102
 Nephrotic syndrome, 16
 B cells, 79
 immunomodulatory drugs, 80
 soluble permeability factors,
 70, 71
 T cells, 78–79
 Non-inferiority randomized controlled trial, 110
 Normocytic-normochromic anemia, 97
 Nuclear factor of Kappa-B (NF- κ B), 48
- O**
 Opossum kidney (OK) cells, 28
 Oral corticosteroid therapy, 131
 Orthostatic proteinuria, 4
- P**
 Pamidronate, 122
 Parietal epithelial cells (PECs), 12
 Parvovirus B19, 123
 Passive Heymann nephritis (PHN), 93
 Pentoxifylline, 56
 Peripheral blood mononuclear cells
 (PBMC), 89
 Peroxisome proliferator activated receptor
 (PPAR)- γ , 33
 Persistent albuminuria, 42
 Phospholipase A2 Receptor 1 (PLA2R1),
 74, 75
 Pirfenidone, 56
 Platelet-derived growth factor (PDGF), 89
 Podocyte disease
 Angptl-4, 93, 94
 CD80, 92, 93
 slit diaphragm, 91
 structural and functional segments, 91
 Polyinosinic:polycytidylic acid (Poly:IC), 92
 Protein-kinase-RNA-like ER kinase (PERK), 49
 Proteinuria
 epidemiology, 3–4
 evaluation of individual, 4, 5
 immune-mediated mechanisms of injury
 (*see* Immune-mediated mechanisms
 of injury)
 measurement, 2–3
 treatment, 5–7
 Proximal tubular cell
 albumin
 apoptosis, 33–34
 endocytosis, 26–27
 FcRn, 28–30
 glomerular filtrate, 25

mechanisms for, 25
 Megalin-Cubilin complex, 27–28
 MWF rats, 26
 tubulo-fibrogenesis, 32–33
 dysfunctional, 30–32
 plasma proteins, 25
 Pseudohyponatremia, 97
 Puromycin aminoglycoside (PA), 93, 96, 102
 Pyridoxamine (vitamin B6), 55

R

Ramipril Efficacy in Nephropathy (REIN) trial, 3, 6
 Reactive oxygen species (ROS), 48
 Receptor-associated protein (RAP), 28
 Receptors for AGE (RAGE), 47
 Reed-Sternberg cells, 88
 Renin-angiotensin-aldosterone system (RAAS), 5, 6, 55, 131
 Renin-angiotensin system (RAS), 54
 Rituximab, 109–110, 133

S

SD/FR nephrotic syndrome, 110
 Serum creatinine, 98
 Severe combined immunodeficiency (SCID), 92
 Shalhoub's hypothesis, 101
 Short therapy, 103
 Sirolimus (rapamycin), 122
 Sodium reabsorption, 96
 Soluble urokinase plasminogen activator receptor (suPAR), 119
 Southwest Pediatric Nephrology Study Group, 103, 104
 Sphingomyelin phosphodiesterase acid-like 3 b protein (SMPDL-3b) expression, 109

Src homology 2 (SH2)/Src homology 3 (SH3), 14–15
 Study of Heart and Renal Protection (SHARP), 54

T

Tapering therapy, 104
 Tissue metalloproteinase inhibitors (TIMPs), 47
 Toll-like receptors (TLRs), 75–77
 Transforming growth factor β (TGF β), 125, 134
 Transgenic (TG), 89, 91, 93
Trypanosoma spp., 120
 Tubulo-fibrogenesis, 32–33
 Tumor necrosis factor α (TNF α), 89, 134
 Tyrosine-protein kinase (Tie2) receptor, 16

U

United Kingdom Prospective Diabetes Study (UKPDS), 43
 Upper respiratory infections (URI), 99, 100
 Urinalysis, 96
 Urinary albumin excretion (UAE), 42
 Urinary albumin-to-creatinine ratio (UACR), 2
 Urinary CD80, 92, 93
 Urine protein-to-creatinine ratio (UPCR), 2, 4
 Urokinase plasminogen receptor (uPAR), 119

V

Vascular endothelial growth factor a (VEGFA), 15
 Visceral epithelial cells, 91, 94
 Vitamin D, 98

W

Wiskott–Aldrich syndrome protein (N-WASP), 15